Purpose:This is a two-arm preliminary efficacy RCT in 120 participants testing a 6-week home-based walking and progressive resistance exercise program (EXCAP©®) vs. standard care on CIPN, interoception, and inflammation. Participants: This study will enroll 120 participants receiving neurotoxic chemotherapy or have completed neurotoxic chemotherapy in the past nine months (i.e., taxane-, platinum-, vinca alkaloid-, epothilone-, or proteasome inhibitor-based chemotherapy). Procedures (methods): Participants will complete questionnaires, clinical assessments, and a blood draw at two time points: pre-intervention (week 0, T1) and post-intervention (approximately week 6, T2).
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Elie Choufani
UNC Hospitals - Nash
Clinical or Medical
Interventional
Cancer (Bladder, Brain and Other Nervous System, Breast, Colorectal, Cervical, Head and Neck, Kidney, Liver, Lung, Melanoma, Pancreatic, Prostate, Sarcoma (bone and soft tissue), Stomach and Esophageal, Thyroid and Other Gland/Endocrine, Leukemia, Lymphoma, Multiple Myeloma, Uterine (endometrial), Ovarian)
22-0495
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
